Caveolin-1 as a potential high-risk prostate cancer biomarker

  • Authors:
    • Jaromir Gumulec
    • Jiri Sochor
    • Marian Hlavna
    • Marketa Sztalmachova
    • Sona Krizkova
    • Petr Babula
    • Roman Hrabec
    • Arne Rovny
    • Vojtech Adam
    • Tomas Eckschlager
    • Rene Kizek
    • Michal Masarik
  • View Affiliations

  • Published online on: December 8, 2011     https://doi.org/10.3892/or.2011.1587
  • Pages: 831-841
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Current diagnostic techniques of prostate cancer cannot efficiently distinguish the latent and low-risk forms from the high-risk significant forms of prostate cancer. Caveolin-1 (Cav-1), except other functions, plays an important role in cell transformation and the process of tumorigenesis. Furthermore, Cav-1 is involved in metastatic processes. It has also been shown that Cav-1 expression is induced under stress conditions, such as oxidative stress. The present study focused on the determination of prognostic markers of aggressive (high-grade) forms of prostate cancer. We determined serum Cav-1 and serum markers of antioxidant activity-glutathione (GSH), 2,2-diphenyl-1-picrylhydrazyl (DPPH), Trolox equivalent antioxidant capacity (TEAC), ferric-reducing antioxidant power (FRAP), N,N-dimethyl-1,4-diaminobenzene (DMPD), free radicals method (FRK) and blue chromium peroxide (Cro) in 97 serum samples (82 prostate cancer patients and 15 controls). We found insignificant differences in Cav-1 between the sera of patients and controls (5.69 in the cancer group vs. 5.42 ng/ml in the control group). However, we found a significant (p<0.004) 2.8-fold elevation of Cav-1 in high tumour stages (TNM T4) compared to lower stages and a significant positive association with histological grading (r=0.29, p=0.028). We also found that in patients with high serum Cav-1 the antioxidant capacity of the body is reduced. These findings indicate that Cav-1 may be an interesting tool for the prediction of disease burden.

Related Articles

Journal Cover

March 2012
Volume 27 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Gumulec J, Sochor J, Hlavna M, Sztalmachova M, Krizkova S, Babula P, Hrabec R, Rovny A, Adam V, Eckschlager T, Eckschlager T, et al: Caveolin-1 as a potential high-risk prostate cancer biomarker. Oncol Rep 27: 831-841, 2012
APA
Gumulec, J., Sochor, J., Hlavna, M., Sztalmachova, M., Krizkova, S., Babula, P. ... Masarik, M. (2012). Caveolin-1 as a potential high-risk prostate cancer biomarker. Oncology Reports, 27, 831-841. https://doi.org/10.3892/or.2011.1587
MLA
Gumulec, J., Sochor, J., Hlavna, M., Sztalmachova, M., Krizkova, S., Babula, P., Hrabec, R., Rovny, A., Adam, V., Eckschlager, T., Kizek, R., Masarik, M."Caveolin-1 as a potential high-risk prostate cancer biomarker". Oncology Reports 27.3 (2012): 831-841.
Chicago
Gumulec, J., Sochor, J., Hlavna, M., Sztalmachova, M., Krizkova, S., Babula, P., Hrabec, R., Rovny, A., Adam, V., Eckschlager, T., Kizek, R., Masarik, M."Caveolin-1 as a potential high-risk prostate cancer biomarker". Oncology Reports 27, no. 3 (2012): 831-841. https://doi.org/10.3892/or.2011.1587